Viewing 0 reply threads
  • Author
    • #17254

      Today, Reata Pharmaceuticals provided a 4th quarter and full year 2020 update on clinical programs. During this meeting, Reata acknowledged the FA Community petition to advance regulator approval of omaveloxolone in FA. Reata also presented additional data from the extension study that supports a disease modifying effect of omav. Reata is reaching out to FDA to request a Type C meeting to continue dialogue on regulatory path forward.

      To read the full press release or listen to the call, click below:

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2021 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account